“As we execute toward major milestones in 2026, we are sharply focused on our strategic priorities across the organization,” said Douglas Love, president and chief executive officer of Annexon (ANNX). “In GA, where no vision-preserving therapies are available for the approximately 8 million people impacted worldwide, we’re eagerly anticipating topline pivotal data from our ARCHER II Phase 3 trial in the fourth quarter of the year. ARCHER II is designed to reproduce the ARCHER Phase 2 data where vonaprument demonstrated the preservation of photoreceptor neurons and vision on multiple measures.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANNX:
- Cyber Risks Threaten Annexon Biosciences’ Clinical Operations, Reputation and Financial Health
- Chardan sees positive read-through to Annexon’s vonaprument from Apellis deal
- Annexon files automatic mixed securities shelf
- Annexon: Solid Cash Runway and 2026 Clinical Catalysts Underpin Buy Rating
- Annexon (ANNX): Late‑Stage Complement Pipeline and Strong Cash Runway Support Attractive Risk‑Reward and Buy Rating